These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15280930)

  • 1. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.
    Pavlenko M; Roos AK; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
    Br J Cancer; 2004 Aug; 91(4):688-94. PubMed ID: 15280930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
    Lechleider RJ; Arlen PM; Tsang KY; Steinberg SM; Yokokawa J; Cereda V; Camphausen K; Schlom J; Dahut WL; Gulley JL
    Clin Cancer Res; 2008 Aug; 14(16):5284-91. PubMed ID: 18698048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.
    Miller AM; Ozenci V; Kiessling R; Pisa P
    J Immunother; 2005; 28(4):389-95. PubMed ID: 16000958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
    McNeel DG; Dunphy EJ; Davies JG; Frye TP; Johnson LE; Staab MJ; Horvath DL; Straus J; Alberti D; Marnocha R; Liu G; Eickhoff JC; Wilding G
    J Clin Oncol; 2009 Sep; 27(25):4047-54. PubMed ID: 19636017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
    Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
    Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
    Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer.
    Tonelli TP; Eickhoff JC; Johnson LE; Liu G; McNeel DG
    Hum Vaccin Immunother; 2024 Dec; 20(1):2395680. PubMed ID: 39208856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety of a viral vector based prostate cancer vaccine strategy.
    Arlen PM; Skarupa L; Pazdur M; Seetharam M; Tsang KY; Grosenbach DW; Feldman J; Poole DJ; Litzinger M; Steinberg SM; Jones E; Chen C; Marte J; Parnes H; Wright J; Dahut W; Schlom J; Gulley JL
    J Urol; 2007 Oct; 178(4 Pt 1):1515-20. PubMed ID: 17707059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
    Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A
    Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
    Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
    Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.
    Meidenbauer N; Harris DT; Spitler LE; Whiteside TL
    Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
    Kim JJ; Yang JS; Nottingham LK; Tang W; Dang K; Manson KH; Wyand MS; Wilson DM; Weiner DB
    Oncogene; 2001 Jul; 20(33):4497-506. PubMed ID: 11494145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
    Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW
    Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
    Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
    Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.